STOCK TITAN

LeMaitre Vascular, Inc. - LMAT STOCK NEWS

Welcome to our dedicated page for LeMaitre Vascular news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on LeMaitre Vascular stock.

LeMaitre Vascular, Inc. (Nasdaq: LMAT) is a leading provider of medical devices and implants for the treatment of peripheral vascular disease, a condition that affects over 200 million people globally. The company develops, manufactures, and markets disposable and implantable vascular devices aimed at addressing the needs of vascular surgeons. LeMaitre Vascular offers a diversified product portfolio that includes angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems.

Headquartered in Burlington, Massachusetts, LeMaitre's products are utilized during open vascular surgeries, primarily focusing on several anatomical areas such as the carotid, lower extremities, upper extremities, and aorta. The company's lower extremities product line generates the highest revenue, followed by the carotid product line. In recent financial updates, the company reported significant growth in sales across various product categories including bovine patches, valvulotomes, and carotid shunts.

LeMaitre Vascular continues to demonstrate robust financial health. For Q3 2023, the company reported a 21% increase in sales and a 49% rise in operating income, driven by price increases and operational efficiencies. Operating income for Q4 2023 was up 46%, reflecting strong sales growth and improved gross margins. In addition, LeMaitre has a share repurchase program and regularly pays dividends to its shareholders, exemplifying its commitment to shareholder value.

Furthermore, LeMaitre Vascular is focused on expanding its global footprint. Sales in the Americas, EMEA, and APAC regions have shown substantial growth, contributing significantly to the company's revenue. The company also emphasizes compliance with global regulatory requirements, ensuring that its products meet stringent quality standards.

LeMaitre frequently engages with investors through earnings calls, providing transparency about its financial performance and strategic outlook. The company remains committed to innovation and development, constantly working on new projects to enhance its product offerings and address emerging market needs.

For more information about LeMaitre Vascular and its latest updates, visit their official website at www.lemaitre.com.

Rhea-AI Summary
LeMaitre Vascular, Inc. to present at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
conferences
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
conferences
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.23%
Tags
none
Rhea-AI Summary

LeMaitre Vascular (LMAT) has secured an exclusive distribution agreement for Aziyo Biologics' cardiovascular patches in the U.S. for three years, with an option to acquire Aziyo's worldwide cardiovascular patch business during the second and third year. The patches, including ProxiCor®, VasCure®, and Tyke®, utilize an extracellular matrix aimed at reducing inflammation and promoting healthy tissue formation. Aziyo reported $6.8 million in sales from these patches in 2022. LeMaitre anticipates a 50% gross margin from patch sales. President David Roberts expressed enthusiasm about enhancing the company's product offerings for vascular and cardiac surgeons. Further financial implications of this agreement will be detailed in LeMaitre’s Q1 2023 earnings call on May 2, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) will announce its Q1 2023 financial results on May 2, 2023, after market closure. A conference call is scheduled for 5:00 PM ET on the same day to discuss the results and outlook for the company. Interested parties can register for the call here. The company provides devices and services for treating peripheral vascular disease, impacting over 200 million people globally, and focuses on the needs of vascular surgeons.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
-
News
Rhea-AI Summary

LeMaitre Vascular (Nasdaq: LMAT) announced the acquisition of its Thai distributor, Prompt Serve, for $688,000. In 2022, Prompt Serve sold approximately $1.5 million of LeMaitre products to Thai hospitals. This acquisition will enable LeMaitre to establish a direct sales presence in Thailand, marking its 29th direct-to-hospital country and 8th in the APAC region. Jacob Petersen, VP of Asia-Pacific, noted this move is part of their ongoing expansion, aiming for over 90% of operations to be direct in the APAC market. Further financial guidance regarding the impact on 2023 revenue and earnings will be provided during the Q1 earnings call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
none
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) will participate in four investor conferences in March 2023. Key events include the 35th Annual Roth Conference on March 13, featuring President David Roberts in a fireside chat at 12:30 PM PT. On March 15, the Oppenheimer 33rd Annual Healthcare Conference will feature CFO JJ Pellegrino at 8:40 AM ET, followed by Roberts presenting at the Barclays Global Healthcare Conference at 2:35 PM ET. Finally, on March 22, Roberts will present at the KeyBanc Life Sciences & MedTech Investor Forum at 3:00 PM ET. LeMaitre provides innovative devices for peripheral vascular disease, serving a global market of over 200 million patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences

FAQ

What is the current stock price of LeMaitre Vascular (LMAT)?

The current stock price of LeMaitre Vascular (LMAT) is $94.04 as of December 26, 2024.

What is the market cap of LeMaitre Vascular (LMAT)?

The market cap of LeMaitre Vascular (LMAT) is approximately 2.1B.

What products does LeMaitre Vascular offer?

LeMaitre Vascular offers a range of medical devices including angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems.

Where is LeMaitre Vascular headquartered?

LeMaitre Vascular is headquartered in Burlington, Massachusetts.

In which medical areas are LeMaitre's products primarily used?

LeMaitre's products are primarily used in open vascular surgeries targeting the carotid, lower extremities, upper extremities, and aorta.

What was the company's financial performance in Q3 2023?

In Q3 2023, LeMaitre reported a 21% increase in sales and a 49% rise in operating income, driven by price increases and operational efficiencies.

How does LeMaitre Vascular engage with its investors?

LeMaitre Vascular engages with investors through earnings calls, providing transparency about its financial performance and strategic outlook. Investors can access these through the company's website.

What regions contribute significantly to LeMaitre's revenue?

LeMaitre's revenue is significantly contributed by sales in the Americas, EMEA, and APAC regions.

Does LeMaitre Vascular pay dividends to its shareholders?

Yes, LeMaitre Vascular regularly pays dividends to its shareholders.

What recent financial achievements has LeMaitre Vascular reported?

LeMaitre reported significant growth across various product lines, including bovine patches, valvulotomes, and carotid shunts, with strong sales and improved gross margins in recent quarters.

How does LeMaitre ensure the quality of its products?

LeMaitre ensures the quality of its products by complying with global regulatory requirements and maintaining stringent quality standards.

Where can I find more information about LeMaitre Vascular?

More information about LeMaitre Vascular can be found on their official website at www.lemaitre.com.

LeMaitre Vascular, Inc.

Nasdaq:LMAT

LMAT Rankings

LMAT Stock Data

2.09B
20.49M
8.85%
94.32%
3.36%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
BURLINGTON